Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 18/20 | 0.81 |
| ▸ | CDK2 | P24941 | 16/20 | 0.81 |
| ▸ | ULK1 | O75385 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644986 | 0.89 | CDK4 (1.00) | CDK4CDK2IGF1R | |
| SCHEMBL5581900 | 0.89 | CDK4 (1.00) | CDK4CDK2IGF1R | |
| SCHEMBL29644990 | 0.89 | CDK4 (1.00) | CDK4CDK2IGF1R | |
| SCHEMBL6644486 | 0.86 | CDK4 (0.86) | CDK4CDK2PTK2DAPK3JAK2 | |
| SCHEMBL6642542 | 0.85 | CDK4 (0.83) | CDK4CDK2PTK2DAPK3JAK2 | |
| SCHEMBL7242055 | 0.82 | CDK4 (0.81) | CDK4CDK2PTK2DAPK3JAK2 | |
| SCHEMBL6648540 | 0.81 | CDK4 (0.76) | CDK4CDK2PTK2DAPK3JAK2 | |
| SCHEMBL7241987 | 0.79 | CDK4 (0.74) | CDK4CDK2PTK2DAPK3JAK2 | |
| SCHEMBL6646695 | 0.79 | CDK4 (0.71) | CDK4CDK2PTK2DAPK3JAK2 | |
| SCHEMBL6786505 | 0.79 | CDK4 (0.73) | CDK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140860-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-22 | — | — | EP | claimed |
| US-6593326-B1 | Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man. | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | claimed |
| EP-1140860-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039101-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | claimed |
| US-20070225209-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20040226056-A1 | Compositions and methods for treating neurological disorders and diseases | MYRIAD GENETICS, INCORPORATED (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225209-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND DISEASES | CLN6, PMP22, PSEN2 | CDK4 2698/4885CDK2 2953/4885ULK1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.